Skip to main content
Premium Trial:

Request an Annual Quote

Diagnoplex Gains Financing Extension

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics developer Diagnoplex today said it has closed a Series A financing extension with Debiopharm Group.

Diagnoplex said today that Debiopharm has committed to invest “a substantial amount” in the company, depending on certain milestones, and has provided half of that commitment up front, although the company did not provide specific financial details about the investment.

Through its initial series A financing round, which included investors Novartis Venture Fund, NeoMed, and Initiative Capital Romandie, Diagnoplex raised CHF 10 million ($10.4 million).

Diagnoplex is currently conducting a multi-center clinical validation study of its Colox test, a blood-based test for early detection of colon cancer that includes centers in Switzerland, Germany, and South Korea.

The firm’s testing platform uses RT-qPCR, initially developed by Stavros Therianos, founder and CEO of Diagnoplex while he was at the University of Rochester, to quantify up to 60 genes at the same time.

"We believe Diagnoplex is well-positioned to address a huge unmet medical need in colon cancer screening,” Thierry Mauvernay, Executive VP of Debiopharm said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more